BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18347528)

  • 1. Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Sageshima J; Herrada E; Tueros L; Roth D; Kupin W; Rosen A; Esquenazi V; Miller J
    Transplantation; 2008 Feb; 85(4):507-16. PubMed ID: 18347528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roohipour R; Carreno MR; Roth D; Ruiz P; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2004 Aug; 78(3):426-33. PubMed ID: 15316372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
    Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
    Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA
    Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
    Clatworthy MR; Friend PJ; Calne RY; Rebello PR; Hale G; Waldmann H; Watson CJ
    Transplantation; 2009 Apr; 87(7):1092-5. PubMed ID: 19352132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
    Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
    Ciancio G; Burke GW; Suzart K; Mattiazzi A; Vaidya A; Roth D; Kupin W; Rosen A; Johnson N; Miller J
    Am J Transplant; 2003 Aug; 3(8):1010-6. PubMed ID: 12859538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
    Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
    Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
    Watson CJ; Bradley JA; Friend PJ; Firth J; Taylor CJ; Bradley JR; Smith KG; Thiru S; Jamieson NV; Hale G; Waldmann H; Calne R
    Am J Transplant; 2005 Jun; 5(6):1347-53. PubMed ID: 15888040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP; Kaczorowski D; Basu A; McCauley J; Marcos A; Donaldson J; Unruh M; Randhawa P; Zeevi A; Shapiro R
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.